https://www.selleckchem.com/pr....oducts/itacnosertib.
Recently, a tool called the positron emission tomography (PET)-assisted reporting system (PARS) was developed and presented to classify lesions in PET/computed tomography (CT) studies in patients with lung cancer or lymphoma. The aim of this study was to validate PARS with an independent group of lung-cancer patients using manual lesion segmentations as a reference standard, as well as to evaluate the association between PARS-based measurements and overall survival (OS). This study retrospectively included 115 patients who had unde
Mi piace
Commento
Condividi
